Novartis India plans rights issue
Novartis India (BSE: NOVARTIND) said it has taken up rights issue. The company is valued at about ₹4,253 crore.
What happened
Novartis India (BSE: NOVARTIND) informed the stock exchanges on 4 November 2026 at 07:46 PM that it has taken up rights issue.
From the filing: "Intimation is hereby given that the record date for determining the rights entitlement for the Rights Issue of partly paid-up shares of the Company shall be Wednesday, November 11, 2026."
Company snapshot
Novartis India is a small-cap company, with a market value of about ₹4,253 crore.
The stock last traded at ₹1,722.4, against a 52-week range of ₹672.3–₹2,588.8 (33.5% below the high).
Before this filing the shares had moved −12.3% over the month and +5.3% over three months. Average daily turnover over the last 20 sessions was about ₹7.16 crore.
Promoters held 70.68% at the end of Q2 FY27. Foreign institutions owned 1.22% and domestic institutions 1.50%.
| Quarter | Revenue | Net profit | EPS (₹) |
|---|---|---|---|
| Q2 FY26 | 90 | 24.2 | 9.81 |
| Q3 FY26 | 86 | 16.1 | 6.52 |
| Q4 FY26 | 91 | 25.3 | 10.23 |
| Q1 FY27 | 104 | 32.2 | 13.05 |
| Q2 FY27 | 56 | -77.5 | -31.41 |
What history shows
BCEIE's records show 3 previous fund raising filings from the company since May 2026.
After those filings, the stock gained 1.3% on average the next trading day (2 filings with price data).
Market-wide, 1,733 fund raising filings with an impact score of 50 or more saw an average next-day move of +0.3%, with 47% rising.
Past reactions describe what happened before; they are not a forecast.
| Date | Filing | Next day | 5 days |
|---|---|---|---|
| 8 Oct 2026 | The Board of Directors of the Company Evonile Pharma Limited… | +1.3% | — |
| 8 Oct 2026 | The Board of Directors of Evonile Pharma Limited (formally known as… | +1.3% | — |
What to watch
- How the money raised is used and, for equity instruments, the dilution for existing shareholders.
In the news
Recent coverage elsewhere (links open the original publisher):
- Novartis CEO unfazed by high-profile clinical failures, maintains long-term revenue goal
- Novartis CEO keeps faith in Avidity deal despite taking $1.9B hit from del-desiran fail
- Evonile Pharma Q2 FY27: First Results After Novartis Exit
- Novartis CEO says company must stay 'courageous' to pursue breakthroughs
- Novartis raised profit outlook in Q3 2026 earnings despite charge
Source
Automatically written from the exchange filing and BCEIE data. Not investment advice. Check the original filing before acting on it.